{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: 3 FDA-approved therapies approved based on PROs and HR-QoL, showing symptom improvement can be clinically significant."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [SHIP NOW]**: Develop automated ePRO reminders to improve patient engagement and data quality in ATTR-CM trials."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸ”´ URGENT]**: FDA requiring PRO data in trials within 12 months, increasing competition for innovative PRO solutions."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Self-selection bias in PRO studies may lead to healthier patients being represented, potentially skewing results."
    }
  ],
  "model": "granite4:tiny-h"
}